Prolyl hydroxylase domain protein 3 and asparaginyl hydroxylase factor inhibiting HIF-1 levels are predictive of tumoral behavior and prognosis in hepatocellular carcinoma

被引:15
|
作者
Ma, Mingyang [1 ,2 ]
Hua, Shuyao [3 ]
Li, Gang [4 ]
Wang, Sumei [3 ]
Cheng, Xue [3 ]
He, Songqing [5 ,6 ,7 ]
Wu, Ping [3 ]
Chen, Xiaoping [1 ,2 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp,Hepat Surg Ctr, Key Lab Organ Transplantat,Minist Educ,Hubei Prov, Wuhan 430030, Peoples R China
[2] Minist Publ Hlth, Wuhan 430030, Peoples R China
[3] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Basic Med, Dept Pathophysiol, Wuhan 430030, Peoples R China
[4] Huazhong Univ Sci & Technol, Liyuan Hosp, Dept Surg, Wuhan 430077, Peoples R China
[5] Guangxi Med Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Nanning 530021, Peoples R China
[6] Guilin Med Univ, Affiliated Hosp, Lab Hepatobiliary & Pancreat Surg, Guilin 541001, Peoples R China
[7] Guangxi Key Lab Mol Med Liver Injury & Repair, Guilin 541001, Peoples R China
基金
中国国家自然科学基金;
关键词
hepatocellular carcinoma; hypoxia-inducible factors; prolyl hydroxylase domain-containing proteins; asparaginyl hydroxylase factor inhibiting HIF-1; prognostic factor; HYPOXIA-INDUCIBLE FACTOR; RENAL-CELL CARCINOMA; COLORECTAL-CANCER; INCREASED EXPRESSION; POOR-PROGNOSIS; PHD3; FIH; PATHWAY; GROWTH; PROLIFERATION;
D O I
10.18632/oncotarget.14677
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hypoxia-inducible factors (HIFs) are key regulators in oxygen homeostasis. Their stabilization and activity are regulated by prolyl hydroxylase domain (PHD)-1, -2, -3 and factor inhibiting HIF (FIH). This study investigated the relation between these oxygen sensors and the clinical behaviors and prognosis of hepatocellular carcinoma (HCC). Tissue microarray and RT-PCR analysis of tumor tissues and adjacent non-tumor liver tissues revealed that mRNA and protein levels of both PHD3 and FIH were lower within tumors. The lower expression of PHD3 in tumor was associated with larger tumor size, incomplete tumor encapsulation, vascular invasion and higher Ki-67 LI (p < 0.05). The lower expression of FIH in tumor was associated with incomplete tumor encapsulation, vascular invasion, as well as higher TNM stage, BCLC stage, microvascular density and Ki-67 LI (p < 0.05). Patients with reduced expression of PHD3 or FIH had markedly shorter disease-free survival (DFS), lower overall survival (OS), or higher recurrence (p < 0.05), especially early recurrence. Patients with simultaneously reduced expression of PHD3 and FIH exhibited the least chance of forming tumor encapsulation, highest TNM stage (p < 0.0083), lowest OS and highest recurrence rate (p < 0.05). Multivariate analysis indicated that a lower expression of FIH independently predicted a poor prognosis in HCC. These findings indicate that downregulation of PHD3 and FIH in HCC is associated with more aggressive tumor behavior and a poor prognosis. PHD3 and FIH may be potential therapeutic targets for HCC treatment.
引用
收藏
页码:12983 / 13002
页数:20
相关论文
共 50 条
  • [1] The Asparaginyl Hydroxylase Factor Inhibiting HIF-1α Is an Essential Regulator of Metabolism
    Zhang, Na
    Fu, Zhenxing
    Linke, Sarah
    Chicher, Johana
    Gorman, Jeffrey J.
    Visk, DeeAnn
    Haddad, Gabriel G.
    Poellinger, Lorenz
    Peet, Daniel J.
    Powell, Frank
    Johnson, Randall S.
    CELL METABOLISM, 2010, 11 (05) : 364 - 378
  • [2] Piceatannol, a hydroxystilbene natural product, stabilizes HIF-1α protein by inhibiting HIF prolyl hydroxylase
    Yum, Soohwan
    Doh, Hea-Jeong
    Hong, Sungchae
    Jeong, Seongkeun
    Kim, Dae-Duk
    Park, Misun
    Jung, Yunjin
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2013, 699 (1-3) : 124 - 131
  • [3] Epigenetic control of prolyl hydroxylase 3 participates in regulating HIF-1α in human carcinoma cell lines
    Venkataraman, Sujatha
    Fitzgerald, Matthew P.
    Jetawattana, Suwimol
    Domann, Frederick E.
    Oberley, Larry W.
    FREE RADICAL BIOLOGY AND MEDICINE, 2006, 41 : S114 - S115
  • [4] Quercetin activates an angiogenic pathway, hypoxia inducible factor (HIF)-1-vascular endothelial growth factor, by inhibiting HIF-prolyl hydroxylase: a structural analysis of quercetin for inhibiting HIF-prolyl hydroxylase
    Jeon, Hyunchu
    Kim, Heejung
    Choi, Daekyu
    Kim, Duksoo
    Park, Shi-Young
    Kim, Yung-Jin
    Kim, Young Mi
    Jung, Yunjin
    MOLECULAR PHARMACOLOGY, 2007, 71 (06) : 1676 - 1684
  • [5] Screening chelating inhibitors of HIF-prolyl hydroxylase domain 2 (PHD2) and factor inhibiting HIF (FIH)
    Flagg, Shannon C.
    Martin, Cristina B.
    Taabazuing, Cornelius Y.
    Holmes, Breanne E.
    Knapp, Michael J.
    JOURNAL OF INORGANIC BIOCHEMISTRY, 2012, 113 : 25 - 30
  • [6] Suppression of hypoxia-inducible factor 1α (HIF-1α) transcriptional activity by the HIF prolyl hydroxylase EGLN1
    To, KKW
    Huang, LE
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (45) : 38102 - 38107
  • [7] DNA methylation analysis of the HIF-1α prolyl hydroxylase domain genes PHD1, PHD2, PHD3 and the factor inhibiting HIF gene FIH in invasive breast carcinomas
    Huang, Katie T.
    Mikeska, Thomas
    Dobrovic, Alexander
    Fox, Stephen B.
    HISTOPATHOLOGY, 2010, 57 (03) : 451 - 460
  • [8] Evidence for inhibition of HIF-1α prolyl hydroxylase 3 activity by four biologically active tetraazamacrocycles
    Cao, Jing
    Geng, Zhirong
    Ma, Xiaoyan
    Wen, Jinghan
    Yin, Yuxin
    Wang, Zhilin
    ORGANIC & BIOMOLECULAR CHEMISTRY, 2012, 10 (19) : 3913 - 3923
  • [9] Inactivation of prolyl hydroxylase domain (PHD) protein by epigallocatechin (EGCG) stabilizes hypoxia-inducible factor (HIF-1α) and induces hepcidin (Hamp) in rat kidney
    Manalo, Dominador J.
    Baek, Jin Hyen
    Buehler, Paul W.
    Struble, Evi
    Abraham, Bindu
    Alayash, Abdu I.
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2011, 416 (3-4) : 421 - 426
  • [10] The Prognostic Significance and Potential Mechanism of Prolyl 3-Hydroxylase 1 in Hepatocellular Carcinoma
    Li, Chunlei
    Zhang, Lilong
    Xu, Yao
    Chai, Dongqi
    Nan, Shengchen
    Qiu, Zhendong
    Wang, Weixing
    Deng, Wenhong
    JOURNAL OF ONCOLOGY, 2022, 2022